Harmony Biosciences Holdings, Inc.
NASDAQHRMY enters the back half of August with a fresh analyst endorsement pulling in one direction and a notably heavy put/call ratio pulling in the other — two signals that don't obviously agree. The most concrete development this week came from the Street. Wolfe Research initiated coverage this morning with an Outperform rating and a $60 price target — roughly 54% above Tuesday's…
HRMY short interest falls 21.8% in one week to 8.05% of float, lowest level since early June.
Snapshot as of 15 Sept 2026
HRMY enters the back half of August with a fresh analyst endorsement pulling in one direction and a notably heavy put/call ratio pulling in the other — two signals that don't obviously agree. The most concrete…
HRMY heads into its August 4 Q2 earnings release with short sellers making a clear statement over the past week. Short interest has climbed nearly 10% in seven days to roughly 9% of the free float — the sharpest weekly…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for HRMY — free to start on ORTEX.
Sign up for free →Open HRMY on ORTEX